Why Atara Biotherapeutics, Inc.’s (ATRA) Stock Is Up 5.84%
As of Friday, November 20, Atara Biotherapeutics, Inc.’s ATRA share price has surged by 5.84%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Michael Rose
Michael Rose
Jenna Brashear
Cynthia McLaughlin
| Share Statistics | ATRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $64.5 | $203.5 | 20% |
|
| Shares Out (Mil) | 15.3 | 55.2 | 26% |
|
| Institutional Ownership | 84.9% | 93.3% | 52% |
|
| Float (Mil) | 4.8 | 40.4 | 12% |
|
| Beta | 0.32 | 1.05 | 18% |
|
| Avg Daily Volume (000s) | 27 | 569 | 23% |
|
| Price Change (52-week) |
(53.9%) | 38.8% | 20% |
|
| Growth | ATRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 16.1% | (10.7%) | 66% |
|
| EPS (5yr) | 15.2% | 15.4% | 57 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.2%) | (15.7%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.090) | ($0.770) | $1.600 | |
| Month Ago EPS | ($0.190) | ($0.950) | $1.545 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.320) | ($1.270) | $1.565 | |
| Year/Year Chg | (40.0%) | (130.0%) | (76.3%) | |
| Financials | ATRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4 | $40 | 5% |
|
| Net Income (TTM) (Mil) | ($15) | ($44) | 26% |
|
| EPS (TTM) | ($1.007) | ($1.400) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | ($35) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $9 | $4 | 27% |
|
| Enterprise Value (Q1) (Mil) | $65 | $142 | 19% |
|
| Valuation | ATRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 1.96 | na |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ATRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 103.3% | 67.6% | 100% |
|
| Net Margin | (368.6%) | (50.8%) | 3% |
|
| ROA | (59.9%) | (47.0%) | 9% |
|
| ROE | 39.2% | (51.8%) | 91% |
|
| Liabilities to Assets | 303.7% | 29.6% | 100% |
|
| F-Score | 3 | 3 | 18% |
|
Atara Biotherapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors